Welcome to our dedicated page for TELA Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TELA Bio, Inc. filings document a commercial-stage medical technology business centered on soft-tissue reconstruction and the OviTex product portfolio for hernia repair and abdominal wall reconstruction. Form 8-K reports cover operating and financial results, revenue updates, Regulation FD disclosures, material agreements, debt and equity capital structure, and other material events tied to the company's medical technology operations.
Proxy materials and governance-related 8-Ks record board composition, director appointments and resignations, executive compensation matters, stockholder meeting proposals, inducement and equity-award practices, and Nasdaq listing-compliance disclosures for TELA common stock listed on the Nasdaq Global Market.
TELA Bio, Inc. director Guy P. Nohra reported compensation-related equity awards in the form of common stock and stock options. On June 9, 2026, he received 11,675 restricted stock units that vest in three equal annual installments beginning on June 9, 2027, and an additional 11,925 restricted stock units that vest on the earlier of June 9, 2027, the next annual meeting of stockholders, or a Change in Control, subject to continued service.
Following these awards, Nohra directly holds 23,600 shares of common stock from one grant and 11,925 shares from the other. He was also granted stock options for 17,335 and 17,550 shares of common stock at an exercise price of $0.935 per share, expiring on June 9, 2036. One option vests in 36 equal monthly installments starting June 9, 2026, and the other vests on the earlier of June 9, 2027, the next annual meeting, or a Change in Control, in each case conditioned on his continued service.
TELA Bio, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders approved an amendment to the Amended and Restated 2019 Equity Incentive Plan that increases the authorized shares issuable under the plan by 3,500,000 shares, expanding the pool available for employee and director equity awards.
Three Class I directors—Joseph Capper, Betty Jo Rocchio and William Plovanic—were re-elected to serve until the 2029 annual meeting. Stockholders also ratified KPMG LLP as independent auditor for the 2026 fiscal year and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. As of April 24, 2026, there were 44,765,928 shares of common stock outstanding.
EW Healthcare Partners funds report a 17.23% beneficial stake in TELA Bio, Inc. common stock, totaling 7,714,709 shares. The stake is held through EW Healthcare Partners Fund 2, L.P., EW Healthcare Partners Fund 2-A, L.P., their general partner entities, and related structures.
The filing states that on June 9, 2026, an operating partner affiliated with the reporting persons was appointed to TELA Bio's Board of Directors. Ownership percentages are based on 44,766,146 shares outstanding as of May 5, 2026, as reported by TELA Bio in a recent Form 10-Q.
TELA Bio, Inc. ownership update: Laurence W. Lytton amended a Schedule 13G/A to report beneficial ownership of 2,442,341 shares of Common Stock, equal to 5.5% of the class.
The filing states the percentage is based on 44,740,371 shares outstanding as of March 16, 2026. The amendment is signed on May 15, 2026.
TELA Bio reported Q1 2026 revenue of $19.1 million and a net loss of $12.3 million. Revenue grew about 3% from the prior-year quarter, driven mainly by higher OviTex unit sales and stronger international demand, partly offset by weaker price mix and slightly lower OviTex PRS volume.
Gross margin slipped to 66% from 68% as higher excess and obsolete inventory charges offset revenue growth. Operating expenses were roughly flat overall, with modestly lower sales and marketing and research and development, and higher general and administrative costs.
The company posted operating cash outflows of $11.2 million and ended the quarter with $39.5 million of cash and cash equivalents. Long‑term debt under its Perceptive term loan remained at $60.0 million, and accumulated deficit increased to $409.8 million, resulting in a stockholders’ deficit of $5.2 million.
TELA Bio, Inc. reported first quarter 2026 results showing modest growth while remaining unprofitable. Revenue was $19.1 million, up 3% from the same period in 2025, driven by 13% unit growth and increasing international sales, partially offset by U.S. product mix headwinds from rapid growth of smaller-sized units.
Gross profit was $12.5 million, with a gross margin of 65.7% versus 67.6% a year earlier, mainly due to higher charges for excess and obsolete inventory. Operating expenses held flat at $23.0 million, resulting in a loss from operations of $10.5 million, similar to 2025. Net loss widened slightly to $12.3 million.
Cash and cash equivalents totaled $39.5 million as of March 31, 2026. Management reiterated its 2026 financial guidance and highlighted a fully built commercial organization, early traction in Europe, and the full U.S. commercial launch of OviTex LTR, aimed at supporting more predictable growth through the remainder of 2026.
TELA Bio, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 9, 2026. Holders of common stock as of April 24, 2026, when 44,765,928 shares were outstanding, may vote online, by phone, mail, or during the meeting.
Stockholders will elect three Class I directors (Joseph Capper, William Plovanic and Betty Jo Rocchio) for terms ending in 2029, ratify KPMG LLP as auditor for 2026, and cast an advisory vote on executive pay. They will also vote on amending the 2019 Equity Incentive Plan to increase authorized shares under the plan by 3,500,000 and on a possible adjournment if support for that amendment is insufficient.
The proxy highlights 2025 performance, including revenue of $20.9 million in Q4 and $80.3 million for the full year, representing 18% and 16% growth versus 2024. It also notes a credit facility of up to $70.0 million with Perceptive Advisors, an initial $60.0 million draw, and a 2025 underwritten registered direct offering of 4,189,000 common shares and pre-funded warrants for 7,523,000 shares that generated approximately $11.6 million in net proceeds.
TELA Bio, Inc. reported preliminary, unaudited revenue of approximately $19.0 million for the quarter ended March 31, 2026. Management prepared this estimate before completing quarter-end closing procedures, and the company’s auditor, KPMG LLP, has not performed any review or assurance work on it. Actual results may differ and will be reflected in the upcoming Form 10‑Q.
The company also announced significant board changes. Chairman Doug Evans and three other directors will retire from the board immediately following the 2026 Annual Meeting, with no departures due to disagreements over operations or policies. The board has nominated Joseph Capper, who is not expected to qualify as independent under Nasdaq rules, to join as a Class I director and become Chairman upon his election. Three new independent directors — Guido Neels, Guy Nohra, and Paul Thomas — will join in different board classes and assume key committee roles after the 2026 Annual Meeting. Subject to their election and appointment, each of these incoming directors and Mr. Capper will receive an initial equity award following the annual meeting, consisting of stock options and restricted stock units that vest over three years.
TELA Bio, Inc. reports 2025 results with revenue of $80.3 million, up from $69.3 million, and a net loss of $38.8 million versus $37.8 million in 2024.
The company is a commercial-stage medical technology business focused on soft-tissue reconstruction, built around its OviTex hernia repair and OviTex PRS plastic and reconstructive surgery portfolios. These reinforced tissue matrices combine ovine-derived biologic material with limited polymer to promote tissue remodeling while maintaining strength.
TELA Bio highlights a large U.S. market opportunity, estimating a total addressable market of about $1.8 billion for OviTex hernia products and $800 million for OviTex PRS. It continues to invest in clinical studies (including BRAVO, BRAVO II and OPERA), product enhancements, and expanded indications, while operating under an exclusive manufacturing and license agreement with Aroa and maintaining a primarily direct U.S. sales force.